Knight Announces Exclusive License Agreement with Ardelyx for Tenapanor
Agreement Advances First-in-Class Tenapanor for IBS-C and Hyperphosphatemia in Canada Ardelyx to Receive Up to CAD 25 Million in Upfront Payment and Subsequent Milestones MONTREAL, QUEBEC–(Marketwired – March 19, 2018) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”) announced today a license agreement with Ardelyx, Inc. (NASDAQ:ARDX)(“Ardelyx”) that provides Knight with exclusive rights to commercialize tenapanor in […]
Knight Reports 2017 Fourth Quarter and Year End Results
MONTREAL, QUEBEC–(Marketwired – March 15, 2018) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2017. All dollar amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. 2017 Highlights Financial […]
Knight Acquires Shares Pursuant to Crescita Rights Offering
MONTREAL, QUEBEC–(Marketwired – March 13, 2018) – Pursuant to the early warning requirements of National Instrument 62-103, Knight Therapeutics Inc. (“Knight”) (TSX:GUD) announced today the acquisition and disposition of securities of Crescita Therapeutics Inc. (“Crescita”). On March 12, 2018, Knight acquired 754,716 common shares of Crescita (“Shares”) at an aggregate price of $400,000 following the […]
Notice of Knight Therapeutics’ 2017 Fourth Quarter and Year End Results Conference Call
MONTREAL, QUEBEC–(Marketwired – March 9, 2018) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its 2017 fourth quarter and year end financial results on Thursday, March 15, 2018 prior to the market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all […]
Knight has Less Skin in the Game with Medimetriks
MONTREAL, QUEBEC–(Marketwired – March 8, 2018) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Medimetriks Pharmaceuticals Inc. (“Medimetriks”) has prepaid US$20 million of Knight’s US$23 million secured strategic loan issued in 2016. The remaining loan receivable balance is US$2 million. Knight has generated approximately US$8.5 million from interest […]
Knight to Participate in Crescita Rights Offering
MONTREAL, QUEBEC–(Marketwired – Feb. 20, 2018) – Pursuant to the early warning requirements of National Instrument 62-103, Knight Therapeutics Inc. (“Knight”) (TSX:GUD) announced today an increase in its interest in the securities of Crescita Therapeutics Inc. (“Crescita”). On February 16, 2018 Knight received 2,079,973 rights (the “Rights”) of Crescita issued under the terms of Crescita’s […]
Knight Reports Third Quarter 2017 Results
MONTREAL, QUEBEC–(Marketwired – Nov. 9, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2017. All dollar amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q3 2017 Highlights Revenues were […]
Notice of Knight Therapeutics’ Third Quarter 2017 Results Conference Call
MONTREAL, QUEBEC–(Marketwired – Nov. 2, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its third quarter 2017 financial results on Thursday, November 9, 2017 prior to the market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to […]
Knight Announces Changing of the Finance Guard
MONTREAL, QUEBEC–(Marketwired – Oct. 10, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Jeffrey Kadanoff, CFO is leaving Knight effective October 13, 2017 in order to pursue other opportunities. Mr. Kadanoff served valiantly in this position since Knight became a publicly listed company in February 2014. Effective […]
Knight Increases Ownership in Crescita
MONTREAL, QUEBEC–(Marketwired – Oct. 10, 2017) – Pursuant to the early warning requirements of National Instrument 62-103, Knight Therapeutics Inc. (TSX:GUD) (“Knight”) announced today an increase in its ownership of Crescita Therapeutics Inc. (“Crescita”). On October 6, 2017, Knight acquired 566,471 common shares of Crescita, representing 4.0% of the issued and outstanding common shares of […]
